Impact of nanoparticles on the immune system

Journal of Biomedical Nanotechnology

Volumn 7, Issue 1, 2011, Pages 193-194

  Dwivedi, Premendra D ^a   Tripathi, Anurag ^a   Ansari, Kausar M ^a   Shanker, Rishi ^a   Das, Mukul ^a  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Adaptive immunity; Innate immunity; Nanomaterials

Indexed keywords

ADAPTIVE IMMUNITY; CHEMICAL COMPOSITIONS; HUMAN EXPOSURES; IMMUNE SYSTEMS; IMMUNOPHENOTYPES; INNATE IMMUNITY; LARGE DEVIATIONS; MODE OF ACTION; NANO DIMENSIONS; NANO SCALE; PHAGOCYTIC ACTIVITY; PHYSIOLOGICAL FUNCTIONS; SERUM PROTEINS; SMALL SIZE; SUB-CELLULAR; TH1/TH2 BALANCE; THROMBOGENECITY;

NANOPARTICLES;

IMMUNOLOGY;

COMPLEMENT; HAPTEN; NANOPARTICLE; PLASMA PROTEIN; CYTOKINE;

ADAPTIVE IMMUNITY; ANTIGENICITY; ARTICLE; CELL PERMEABILIZATION; CELLULAR IMMUNITY; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; INNATE IMMUNITY; MACROPHAGE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSIOLOGY; PROTEIN BINDING; TH1 CELL; TH2 CELL; THROMBOGENESIS; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECT; IMMUNOLOGY; T LYMPHOCYTE;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; NANOPARTICLES; T-LYMPHOCYTES;

EID: 79957705981     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2011.1264     Document Type: Article

References (10)

1. M. A. Dobrocolskaia and S. E. Mcneil, Immunological properties of engineered nanomaterials. Nat. Nano. 2, 469 (2007).
2. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram, I. F. McKenzie, and M. Plebanski, Size-dependent immunogenicity: Therapeutic and protective properties of nanovaccines against tumors. J. Immunol. 173, 3148 (2004).
3. P. L. Mottram, D. Leong, B. Crimeen-Irwin, S. Gloster, S. D. Xiang, J. Meanger, R. Ghildyal, N. Vardaxis, and M. Plebanski, Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 4, 73 (2007).
4. A. Chanan-Khan, J. Szebeni, S. Savay, L. Liebes, N. M. Rafique, C. R. Alving, and F. M. Muggia, Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): Possible role in hypersensitivity reactions. Ann. Oncol. 14, 1430 (2003).
5. J. Szebeni, Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology 216, 106 (2005).
6. S. T. Reddy, A. J. van der Vlies, E. Simeoni, V. Angeli, G. J. Randolph, C. P. O'Neil, L. K. Lee, M. A. Swartz, and J. A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25, 1159 (2007).
7. T. Fifis, A. Gamvrellis, B. Crimeen-Irwin, G. A. Pietersz, J. Li, P. L. Mottram, I. F. McKenzie, and M. Plebanski, Size-dependent immunogenicity: Therapeutic and protective properties of nanovaccines against tumors. J. Immunol. 173, 3148 (2004).
8. M. van Zijverden and B. Granum, Adjuvant activity of particulate pollutants in different mouse models. Toxicology 152, 69 (2000).
9. U. C. Nygaard, J. S. Hansen, M. Samuelsen, T. Alberg, C. D. Marioara, and M. Løvik, Single-walled and multi-walled carbon nanotubes promote allergic immune responses in mice. Toxicol. Sci. 109, 113 (2009).
10. T. Toyama, H. Matsuda, I. Ishida, M. Tani, S. Kitaba, S. Sano, and I. Katayamal, A case of toxic epidermal necrolysis-like dermatitis evolving from contact dermatitis of the hands associated with exposure to dendrimers. Contact Dermatitis 59, 122 (2008).